

Please type a plus sign (+) in this box

+

PTO/SB (12-97)

OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Application Number

10/580,480

International Application Number

PCT/US04/039221

I.A. Filing Date

November 23, 2004

Priority Date

November 26, 2003

First Named Inventor

Miller

Group Art Unit / Conf. No.:

Not Yet Assigned

Examiner Name

Not Yet Assigned

Attorney Docket Number

24852-504 NATL

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date
NOI	A1	4,522,811	06/11/85	Eppstein, <i>et al.</i>	514	2	07/08/82
	A2	5,369,108	11/29/94	Breslow, <i>et al.</i>	514	266	10/04/91
	A3	5,608,108	03/04/97	Marks, <i>et al.</i>	562	621	04/17/95
	A4	5,700,811	12/23/97	Breslow, <i>et al.</i>	514	314	05/19/94
	A5	5,932,616	08/03/99	Breslow, <i>et al.</i>	514	532	04/04/94
	A6	6,087,367	07/11/00	Breslow, <i>et al.</i>	514	266	05/18/99
	A7	6,511,990	01/28/03	Breslow, <i>et al.</i>	514	314	08/24/00
	A8	2003/0235588	12/25/03	Richon, <i>et al.</i>	514	575	02/14/03
	A9	2004/0087657	05/06/04	Richon, <i>et al.</i>	514	575	10/16/02

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	English Yes No
NOI	B1	WO 97/11366	Merck & Co., Inc.	March 27, 1977	X
	B2	WO 98/48825	The Salk Institute for Biological Studies	November 5, 1998	X
	B3	WO 00/08048	Fujisawa Pharmaceuticals Co., Ltd.	February 17, 2000	X
	B4	WO 05/348800	Aton Pharma, Inc.	April 21, 2005	X
	B5	WO 05/053610	Aton Pharma, Inc.	June 16, 2005	X

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
NOI	C1	Abe, E., <i>et al.</i> , Proc. Natl. Acad. Sci. (USA) 78:4990-4994 (1981)
	C2	Andrews <i>et al.</i> , International J. Parasitology 30:761-768 (2000)
	C3	Archer, S. <i>et al.</i> , PNAS 95:6791-96 (1998)
	C4	Biggs, <i>et al.</i> , J. of Pharmaceutical Sciences, 61:1739-1745
	C5	Brosch <i>et al.</i> , Plant Cell 7, 1941-1950 (1995)
	C6	Butler, L.M. <i>et al.</i> , Cancer Res. 60:5165-5170 (2000)
	C7	Cohen, L.A. <i>et al.</i> , Anticancer Research 19:4999-5006 (1999)
	C8	Cousens <i>et al.</i> , J. Biol. Chem. 254, 1716-1723 (1979)
	C9	Darkin-Rattray <i>et al.</i> , Proc. Natl. Acad. Sci. USA 93, 13143-13147 (1996)
	C10	Dressel, U. <i>et al.</i> , Anticancer Research 20(2A):1017-22 (2000)
	C11	Ebert, P. S., <i>et al.</i> , Cancer Res. 36: 1809-1813 (1976)
	C12	Finnin, M.S., <i>et al.</i> , Nature 401:188-193 (1999)
	C13	Frey <i>et al.</i> , Bioorganic & Med. Chem. Lett., 12, 3443-3447 (2002)
	C14	Friend, C., <i>et al.</i> , Proc. Natl. Acad. Sci., U. S., 68:378-382 (1971)

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
NO ↓	C15	Grunstein, M., <i>Nature</i> , 389: 349-52 (1997)
	C16	Guan <i>et al.</i> , <i>Cancer Research</i> , 60:749-755 (2000)
	C17	Hayashi, M., <i>et al.</i> , <i>Gann</i> 70: 235-238 (1979)
	C18	Huberman, E. <i>et al.</i> , <i>Proc. Natl. Acad. Sci. (USA)</i> 76: 1293-1297 (1979)
	C19	Kijima <i>et al.</i> , <i>J Biol. Chem.</i> 268:22429-22435 (1993)
	C20	Kim <i>et al.</i> , <i>Oncogene</i> , 18: 2461-2470 (1999)
	C21	Koghe <i>et al.</i> , <i>Biochem. Pharmacol.</i> 56: 1359-1364 (1998)
	C22	Kwon <i>et al.</i> , <i>PNAS</i> 95: 3356-3361 (1998)
	C23	Lea <i>et al.</i> , <i>Anticancer Research</i> , 15, 879-873 (1995)
	C24	Lin, R.J. <i>et al.</i> , <i>Nature</i> 391:811-14 (1998)
	C25	Lotem, J., <i>et al.</i> , <i>Int. J. Cancer</i> 15: 731-740 (1975)
	C26	Lotem, J. <i>et al.</i> , <i>Proc. Natl. Acad. Sci. (USA)</i> 76: 5158-5162 (1979)
	C27	Marks <i>et al.</i> , <i>Cancer Res.</i> 47:659 (1987)
	C28	Marks, P.A. <i>et al.</i> , <i>J. Natl. Cancer Inst.</i> , 92:1210-1215 (2000)
	C29	McBain <i>et al.</i> , <i>Biochem. Pharm.</i> 53: 1357-1368 (1997)
	C30	Metcalfe, D., <i>et al.</i> , <i>Science</i> , 229: 16-22 (1985)
	C31	Morin, M. J., <i>et al.</i> , <i>Cancer Res.</i> 44: 2807-2812 (1984)
	C32	Nakajima <i>et al.</i> , <i>Ex. Cell Res.</i> 241,126-133 (1998)
	C33	Qiu <i>et al.</i> , <i>Mol. Biol. Cell</i> 11, 2069-2083 (2000)
	C34	Reuben, R. C., <i>et al.</i> , <i>Proc. Natl. Acad. Sci. (USA)</i> 73: 862-866 (1976)
	C35	Richon <i>et al.</i> , <i>Proc. Natl. Acad. Sci. USA</i> , 93:5705-5708 (1996)
	C36	Richon, V. M. <i>et al.</i> , <i>Proc. Natl. Acad. Sci., USA</i> , 95:3003-3007 (1998)
	C37	Sachs, L., <i>Nature (Lond.)</i> 274: 535 (1978)
	C38	Saito <i>et al.</i> , <i>Proc. Natl. Acad. Sci. USA</i> 96, 4592-4597 (1999)
	C39	Scher, W. <i>et al.</i> , <i>Exp. Hematol.</i> 11: 490-498 (1983)
	C40	Scher, W., <i>et al.</i> , <i>Biochem. & Biophys. Res. Comm.</i> 109: 348-354 (1982)
	C41	Schwartz, E. L. <i>et al.</i> , <i>Cancer Res.</i> 42: 2651-2655 (1982)
	C42	Schwartz, E. L., <i>et al.</i> , <i>Cancer Res.</i> 43: 2725-2730 (1983)
	C43	Schwartz, E. L., <i>et al.</i> , <i>Proc. Am. Assoc. Cancer Res.</i> 24: 18 (1983)
	C44	Su <i>et al.</i> , <i>Cancer Research</i> , 60: 3137-3142 (2000)
	C45	Sugano, H., <i>et al.</i> , <i>Bibl. Hematol.</i> 39: 943-954 (1973)
	C46	Takenaga, K., <i>et al.</i> , <i>Cancer Res.</i> 40: 914-919 (1980)
	C47	Tanaka, M., <i>et al.</i> , <i>Proc. Natl. Acad. Sci. (USA)</i> 72: 1003-1006 (1975)
	C48	Terada, M., <i>et al.</i> , <i>Proc. Natl. Acad. Sci. (USA)</i> 75: 2795-2799 (1978)
	C49	Van Lint, C. <i>et al.</i> , <i>Gene Expression</i> 5:245-53 (1996)
	C50	Wang <i>et al.</i> , <i>Cancer Research</i> , 59, 2766-2799 (1999)
	C51	Yoshida, M. <i>et al.</i> , <i>J. Biol. Chem.</i> , 265:17174-17179, (1990)
	C52	International Search Report for PCT/US04/039221 mailed November 3, 2005

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	/Taylor Oh/ (09/09/2010)	Date Considered	09/09/2010
--------------------	--------------------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) in this box

+

PTO/SB (12-97)
OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Application Number	10/580,480
International Application Number	PCT/US04/039221
I.A. Filing Date	November 23, 2004
Priority Date	November 26, 2003
First Named Inventor	Miller
Group Art Unit / Conf. No.:	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	24852-504 NATL

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date
NOI	A1	4,522,811	06/11/85	Eppstein, <i>et al.</i>	514	2	07/08/82
	A2	5,369,108	11/29/94	Breslow, <i>et al.</i>	514	266	10/04/91
	A3	5,608,108	03/04/97	Marks, <i>et al.</i>	562	621	04/17/95
	A4	5,700,811	12/23/97	Breslow, <i>et al.</i>	514	314	05/19/94
	A5	5,932,616	08/03/99	Breslow, <i>et al.</i>	514	532	04/04/94
	A6	6,087,367	07/11/00	Breslow, <i>et al.</i>	514	266	05/18/99
	A7	6,511,990	01/28/03	Breslow, <i>et al.</i>	514	314	08/24/00
	A8	2003/0235588	12/25/03	Richon, <i>et al.</i>	514	575	02/14/03
	A9	2004/0087657	05/06/04	Richon, <i>et al.</i>	514	575	10/16/02

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	English Yes No
NOI	B1	WO 97/11366	Merck & Co., Inc.	March 27, 1977	X
	B2	WO 98/48825	The Salk Institute for Biological Studies	November 5, 1998	X
	B3	WO 00/08048	Fujisawa Pharmaceuticals Co., Ltd.	February 17, 2000	X
	B4	WO 05/348800	Aton Pharma, Inc.	April 21, 2005	X
	B5	WO 05/053610	Aton Pharma, Inc.	June 16, 2005	X

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
NOI	C1	Abe, E., <i>et al.</i> , Proc. Natl. Acad. Sci. (USA) 78:4990-4994 (1981)
	C2	Andrews <i>et al.</i> , International J. Parasitology 30:761-768 (2000)
	C3	Archer, S. <i>et al.</i> , PNAS 95:6791-96 (1998)
	C4	Biggs, <i>et al.</i> , J. of Pharmaceutical Sciences, 61:1739-1745
	C5	Brosch <i>et al.</i> , Plant Cell 7, 1941-1950 (1995)
	C6	Butler, L.M. <i>et al.</i> , Cancer Res. 60:5165-5170 (2000)
	C7	Cohen, L.A. <i>et al.</i> , Anticancer Research 19:4999-5006 (1999)
	C8	Cousens <i>et al.</i> , J. Biol. Chem. 254,1716-1723 (1979)
	C9	Darkin-Rattray <i>et al.</i> , Proc. Natl. Acad. Sci. USA 93,13143-13147 (1996)
	C10	Dressel, U. <i>et al.</i> , Anticancer Research 20(2A):1017-22 (2000)
	C11	Ebert, P. S., <i>et al.</i> Cancer Res. 36: 1809-1813 (1976)
	C12	Finnin, M.S., <i>et al.</i> , Nature 401:188-193 (1999)
	C13	Frey <i>et al.</i> , Bioorganic & Med. Chem. Lett., 12, 3443-3447 (2002)
	C14	Friend, C., <i>et al.</i> , Proc. Natl. Acad. Sci., U. S., 68:378-382 (1971)

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
NOI	C15	Grunstein, M., <i>Nature</i> , 389: 349-52 (1997)
	C16	Guan <i>et al.</i> , <i>Cancer Research</i> , 60,749-755 (2000)
	C17	Hayashi, M., <i>et al.</i> , <i>Gann</i> 70: 235-238 (1979)
	C18	Huberman, E. <i>et al.</i> , <i>Proc. Natl. Acad. Sci. (USA)</i> 76: 1293-1297 (1979)
	C19	Kijima <i>et al.</i> , <i>J Biol. Chem.</i> 268,22429-22435 (1993)
	C20	Kim <i>et al.</i> , <i>Oncogene</i> , 18: 2461-2470 (1999)
	C21	Koghe <i>et al.</i> , <i>Biochem. Pharmacol.</i> 56: 1359-1364 (1998)
	C22	Kwon <i>et al.</i> , <i>PNAS</i> 95: 3356-3361 (1998)
	C23	Lea <i>et al.</i> , <i>Anticancer Research</i> , 15, 879-873 (1995)
	C24	Lin, R.J. <i>et al.</i> , <i>Nature</i> 391:811-14 (1998)
	C25	Lotem, J., <i>et al.</i> , <i>Int. J. Cancer</i> 15: 731-740 (1975)
	C26	Lotem, J. <i>et al.</i> , <i>Proc. Natl. Acad. Sci. (USA)</i> 76: 5158-5162 (1979)
	C27	Marks <i>et al.</i> , <i>Cancer Res.</i> 47:659 (1987)
	C28	Marks, P.A. <i>et al.</i> , <i>J. Natl. Cancer Inst.</i> , 92:1210-1215 (2000)
	C29	McBain <i>et al.</i> , <i>Biochem. Pharm.</i> 53: 1357-1368 (1997)
	C30	Metcalf, D., <i>et al.</i> , <i>Science</i> , 229: 16-22 (1985)
	C31	Morin, M. J., <i>et al.</i> , <i>Cancer Res.</i> 44: 2807-2812 (1984)
	C32	Nakajima <i>et al.</i> , <i>Ex. Cell Res.</i> 241,126-133 (1998)
	C33	Qiu <i>et al.</i> , <i>Mol. Biol. Cell</i> 11, 2069-2083 (2000)
	C34	Reuben, R. C., <i>et al.</i> , <i>Proc. Natl. Acad. Sci. (USA)</i> 73: 862-866 (1976)
	C35	Richon <i>et al.</i> , <i>Proc. Natl. Acad. Sci. USA</i> , 93:5705-5708 (1996)
	C36	Richon, V. M. <i>et al.</i> , <i>Proc. Natl. Acad. Sci., USA</i> , 95:3003-3007 (1998)
	C37	Sachs, L., <i>Nature (Lond.)</i> 274: 535 (1978)
	C38	Saito <i>et al.</i> , <i>Proc. Natl. Acad. Sci. USA</i> 96, 4592-4597 (1999)
	C39	Scher, W. <i>et al.</i> , <i>Exp. Hematol.</i> 11: 490-498 (1983)
	C40	Scher, W., <i>et al.</i> , <i>Biochem. & Biophys. Res. Comm.</i> 109: 348-354 (1982)
	C41	Schwartz, E. L. <i>et al.</i> , <i>Cancer Res.</i> 42: 2651-2655 (1982)
	C42	Schwartz, E. L., <i>et al.</i> , <i>Cancer Res.</i> 43: 2725-2730 (1983)
	C43	Schwartz, E. L., <i>et al.</i> , <i>Proc. Am. Assoc. Cancer Res.</i> 24: 18 (1983)
	C44	Su <i>et al.</i> , <i>Cancer Research</i> , 60: 3137-3142 (2000)
	C45	Sugano, H., <i>et al.</i> , <i>Bibl. Hematol.</i> 39: 943-954 (1973)
	C46	Takenaga, K., <i>et al.</i> , <i>Cancer Res.</i> 40: 914-919 (1980)
	C47	Tanaka, M., <i>et al.</i> , <i>Proc. Natl. Acad. Sci. (USA)</i> 72: 1003-1006 (1975)
	C48	Terada, M., <i>et al.</i> , <i>Proc. Natl. Acad. Sci. (USA)</i> 75: 2795-2799 (1978)
	C49	Van Lint, C. <i>et al.</i> , <i>Gene Expression</i> 5:245-53 (1996)
	C50	Wang <i>et al.</i> , <i>Cancer Research</i> , 59, 2766-2799 (1999)
	C51	Yoshida, M. <i>et al.</i> , <i>J. Biol. Chem.</i> , 265:17174-17179, (1990)
	C52	International Search Report for PCT/US04/039221 mailed November 3, 2005

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	/Taylor Oh/ (09/09/2010)	Date Considered	09/09/2010
--------------------	--------------------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.